Antibodies and methods of use thereof

US11993653B2 · kind B2 · utility

Assignees

• Agenus Inc. · US
• LUDWIG INSTITUTE FOR CANCER RESEARCH LTD · GB
• Memorial Sloan Kettering Cancer Center · US

Inventors

• Marc van Dijk · Bosch en Duin, NL
• Cornelia Anne Mundt · Lörrach, DE
• Gerd Ritter · New York, US
• David Schaer · Mamaroneck, US
• Jedd D. Wolchok · New York, US
• Taha Merghoub · New York, US
• Nicholas Stuart Wilson · Melbourne, AU
• David Adam Savitsky · Boxford, US
• Mark A. Findeis · Belmont, US
• Roberta Zappasodi · New York, US
• Rikke Baek HOLMGAARD · New York, US
• Jean-Marie Cuillerot · Somerville, US
• Igor Proscurshim · Carlisle, US
• Olga Shebanova · Somerville, US

Key dates

• Filing date: Jun 7, 2019
• Grant date: May 28, 2024
• Expiry date: Mar 31, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided are antibodies that specifically bind to CTLA-4 and/or PD-1 and antagonize CTLA-4 and/or PD-1 function. Also provided are pharmaceutical compositions and kits comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies either alone or in combination.